Trevi Therapeutics' Participation in Key Investor Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a leading clinical-stage biopharmaceutical company focused on developing innovative treatments for significant health challenges, is set to engage with investors at a series of important conferences this April. The company aims to update attendees on its groundbreaking investigational therapy, Haduvio™, designed to tackle chronic cough related to idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Details of Upcoming Conferences
Needham Virtual Healthcare Conference
Scheduled from April 7 to 10, 2025, Trevi will be presenting on April 7, with a corporate presentation from 11:00 to 11:40 a.m. ET. Key executives, including Jennifer Good, the President and CEO, and Farrell Simon, the Chief Commercial Officer, will be representing the company. Investors interested in Trevi's innovative approaches are encouraged to attend this presentation.
Jones Healthcare and Technology Innovation Conference
This conference will take place on April 8 and 9, 2025, in a vibrant setting. Trevi will be presenting on April 9, from 11:00 to 11:20 a.m. PT, led by Jennifer Good. This session aims to provide insights into Trevi's advancements and the promising potential of Haduvio in addressing chronic cough challenges.
Piper Sandler Spring Biopharma Symposium
On April 16 and 17, 2025, Trevi representatives, including Jennifer Good and James Cassella, the Chief Development Officer, will explore valuable discussions on Trevi’s scientific developments and the distinct aspects of Haduvio’s efficacy and safety.
About Trevi Therapeutics, Inc.
Trevi Therapeutics is dedicated to addressing the unmet needs of patients suffering from chronic cough, especially those affected by IPF and RCC. Haduvio, which is an investigational oral formulation of nalbuphine, has shown hopeful potential as the first therapy to significantly reduce chronic cough frequency among these populations. As chronic cough is reported to affect a staggering 85% of IPF patients, Trevi's ongoing clinical developments are essential in providing a new avenue for relief where none currently exists.
The implications of chronic cough, with its ability to disrupt daily life by causing up to 1,500 coughs a day, highlight the need for effective treatments. Without approved options, Trevi's Haduvio may represent a transformative approach by acting on the cough reflex with a dual mechanism, targeting both central and peripheral aspects.
Chronic and Refractory Chronic Cough: A Growing Concern
Chronic cough extends beyond mere discomfort; it presents a considerable challenge for millions estimated to be affected. Specifically, refractory chronic cough, which lasts over eight weeks despite other treatments, lacks approved therapies in the U.S. This condition affects around 2-3 million individuals nationwide, creating significant burdens for patients and their families.
As Trevi Therapeutics seeks to propose Haduvio as the trade name for the oral formulation of nalbuphine ER, ongoing initiatives aim to clarify its safety and efficacy more robustly. Though not currently scheduled by the U.S. Drug Enforcement Agency, the drug’s impact could redefine ways chronic cough is approached medically.
Engaging with Investors
Trevi’s commitment to fostering transparent communication with investors is a crucial component of their strategy. By announcing their plans at these conferences, Trevi Therapeutics not only highlights its ongoing work but also its dedication to transforming health outcomes for those plagued by chronic cough and IPF.
For those who wish to follow Trevi's journey and learn more about their innovative therapies, keeping an eye on the upcoming presentations and updates from these conferences will be vital.
Frequently Asked Questions
What is Trevi Therapeutics, Inc. known for?
Trevi Therapeutics is recognized for developing the investigational therapy Haduvio™ aimed at treating chronic cough associated with IPF and RCC.
When will Trevi be participating in investor conferences?
Trevi is scheduled to participate in several investor conferences throughout April 2025, including the Needham Virtual Healthcare Conference.
What is Haduvio™?
Haduvio™ is Trevi's investigational therapy designed to reduce chronic cough by targeting specific opioid receptors involved in cough reflex sensitivity.
How prevalent is chronic cough in IPF patients?
Chronic cough affects approximately 85% of patients with idiopathic pulmonary fibrosis (IPF), significantly impacting their quality of life.
Is there a treatment for refractory chronic cough?
Currently, there are no approved therapies for refractory chronic cough in the U.S., making Trevi's research vital for patients suffering from this debilitating condition.
